Results in terms of prognostic impact and clinical burden, while mainly based on studies with a low sample size, indicated a high unmet need for novel efficacious therapies for patients with advanced NSCLC and EGFR Exon 20ins. This evidence concerns the gene EGFR and non-small cell lung carcinoma.